3.238.176.43
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Home The Ophthalmic Project | AAO TED Roundtable Discussion Part 2

Thyroid Eye Disease-AAO

Facebook
Twitter
LinkedIn
Email

The Ophthalmic Project | AAO TED Roundtable Discussion Part 2

Read More
By rd360stg
The Ophthalmic Project
December 23, 2021
By rd360stg
Michael Kazim, MD discusses AAO Presentation
December 17, 2021
By rd360stg
Coupled medical and surgical treatment needed for TED
December 2, 2021
By rd360stg
POLL: Do you believe all TED is inflammatory/active?
November 30, 2021
-Advertisement-
-Advertisement-
-Advertisement=-
By rd360stg
QUIZ: Understanding the Natural History of Thyroid Eye Disease
November 27, 2021
By rd360stg
Teprotumumab adherence rates are high in patients with TED
November 17, 2021
By rd360stg
Teprotumumab-related adverse events common but mild
November 15, 2021
By rd360stg
Healthcare resource utilization high among patients with TED
November 13, 2021
-Advertisement-
-Advertisement-
-Advertisement=-
By rd360stg
Case report highlights TED after COVID-19 vaccine in patient with Graves’ Disease history
October 8, 2021
By rd360stg
Mycophenolate mofetil appears to be effective second-line treatment for thyroid eye disease
June 7, 2021
By rd360stg
What is a Rainbow Brow?
May 17, 2021
By rd360stg
Is teprotumumab better than steroids in TED associated compressive optic neuropathy?
May 16, 2021
-Advertisement-
-Advertisement-
Videos
All
The Ophthalmic Project | AAO TED Roundtable Discussion Part 2
28 Dec, 2021

The Ophthalmic Project
23 Dec, 2021
Michael Kazim, MD discusses AAO Presentation
17 Dec, 2021
Quizzes
All
QUIZ: Understanding the Natural History of Thyroid Eye Disease
27 Nov, 2021

Polls
All
POLL: Do you believe all TED is inflammatory/active?
30 Nov, 2021

-Advertisement-
-Advertisement-

Contact

Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809
+908-505-8899
info@ihmholdings.com

QUICK LINKS

Social Links

© 2022 IHM. RD 360 is a trademark of International Healthcare Media, LLC. All rights Reserved
-Advertisement-
-Advertisement-